10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be announcing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $142.50 million for the quarter. 10x Genomics has set its Q3 2025 guidance at EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.32) earnings per share. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

TXG opened at $12.90 on Thursday. The stock has a market capitalization of $1.61 billion, a PE ratio of -18.43 and a beta of 2.05. The firm’s fifty day moving average price is $12.87 and its 200 day moving average price is $11.49. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $18.21.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at $6,079,845.52. This represents a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares of the company’s stock, valued at $13,043,850.68. This represents a 0.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 39,149 shares of company stock worth $539,865 in the last 90 days. Corporate insiders own 9.39% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

A number of institutional investors and hedge funds have recently bought and sold shares of TXG. EverSource Wealth Advisors LLC lifted its holdings in 10x Genomics by 203.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock valued at $87,000 after acquiring an additional 5,025 shares during the last quarter. Focus Partners Wealth acquired a new stake in 10x Genomics in the 1st quarter valued at about $92,000. Sei Investments Co. acquired a new stake in 10x Genomics in the 2nd quarter valued at about $151,000. HUB Investment Partners LLC acquired a new stake in 10x Genomics in the 2nd quarter valued at about $152,000. Finally, Orion Porfolio Solutions LLC acquired a new stake in 10x Genomics in the 2nd quarter valued at about $158,000. 84.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Morgan Stanley cut their price target on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday, August 12th. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a report on Monday, August 11th. Zacks Research raised shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Piper Sandler assumed coverage on shares of 10x Genomics in a report on Thursday, September 11th. They set a “neutral” rating and a $15.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the stock a “hold” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $13.65.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.